Results 21 to 30 of about 4,485 (189)

Development of a latency model for HIV-1 subtype C and the impact of long terminal repeat element genetic variation on latency reversal [PDF]

Journal of Virus Eradication
Sub-Saharan Africa accounts for almost 70 % of people living with HIV (PLWH) worldwide, with the greatest numbers centred in South Africa where 98 % of infections are caused by subtype C (HIV-1C).
Shreyal Maikoo, Robert-Jan Palstra, Krista L. Dong, Tokameh Mahmoudi, Thumbi Ndung'u, Paradise Madlala   +5 more
doaj   +3 more sources

Catchet-MS identifies IKZF1-targeting thalidomide analogues as novel HIV-1 latency reversal agents. [PDF]

Nucleic Acids Res, 2022
A major pharmacological strategy toward HIV cure aims to reverse latency in infected cells as a first step leading to their elimination. While the unbiased identification of molecular targets physically associated with the latent HIV-1 provirus would be ...
Ne E, Crespo R, Izquierdo-Lara R, Rao S, Koçer S, Górska A, van Staveren T, Kan TW, van de Vijver D, Dekkers D, Rokx C, Moulos P, Hatzis P, Palstra RJ, Demmers J, Mahmoudi T.   +15 more
europepmc   +3 more sources

Ex vivo analysis identifies effective HIV-1 latency–reversing drug combinations [PDF]

Journal of Clinical Investigation, 2015
Reversal of HIV-1 latency by small molecules is a potential cure strategy. This approach will likely require effective drug combinations to achieve high levels of latency reversal. Using resting CD4+ T cells (rCD4s) from infected individuals, we developed an experimental and theoretical framework to identify effective latency-reversing agent (LRA ...
Laird, Gregory M, Bullen, C Korin, Rosenbloom, Daniel IS, Martin, Alyssa R, Hill, Alison L, Durand, Christine M, Siliciano, Janet D, Siliciano, Robert F   +7 more
openaire   +5 more sources

HSF1 inhibition attenuates HIV-1 latency reversal mediated by several candidate LRAs In Vitro and Ex Vivo. [PDF]

Proc Natl Acad Sci U S A, 2020
HIV-1 latency is a major barrier to cure. Identification of small molecules that destabilize latency and allow immune clearance of infected cells could lead to treatment-free remission.
Timmons A, Fray E, Kumar M, Wu F, Dai W, Bullen CK, Kim P, Hetzel C, Yang C, Beg S, Lai J, Pomerantz JL, Yukl SA, Siliciano JD, Siliciano RF.   +14 more
europepmc   +3 more sources

Modulation of IRF7-driven transcription as a strategy to control HIV-1 latency [PDF]

Frontiers in Immunology
BackgroundThe persistence of latent HIV-1 reservoirs remains a major barrier to achieving a cure for HIV. While latency-reversing agents (LRAs) have been extensively studied, latency-promoting agents (LPAs) offer a complementary strategy to silence viral
Ifeanyi Jude Ezeonwumelu, Ifeanyi Jude Ezeonwumelu, Edurne Garcia-Vidal, Edurne Garcia-Vidal, Eudald Felip, Eudald Felip, Eudald Felip, Sara Cabrero-de las Heras, Sara Cabrero-de las Heras, Bonaventura Clotet, Bonaventura Clotet, Roger Badia, Roger Badia, Ester Ballana, Ester Ballana, Ester Ballana, Eva Riveira-Muñoz, Eva Riveira-Muñoz, Maria Nevot, Maria Nevot   +19 more
doaj   +2 more sources

Identification of celastrol as a novel HIV-1 latency reversal agent by an image-based screen. [PDF]

PLoS One, 2021
Although current antiretroviral therapies (ART) are successful in controlling HIV-1 infection, a stable viral reservoir reactivates when ART is discontinued. Consequently, there is a major research effort to develop approaches to disrupt the latent viral reservoir and enhance the immune system’s ability to clear HIV-1.
Liu H, Hu PW, Dubrulle J, Stossi F, Nikolai BC, Mancini MA, Rice AP.   +6 more
europepmc   +6 more sources

Differentiation into an Effector Memory Phenotype Potentiates HIV-1 Latency Reversal in CD4⁺ T Cells. [PDF]

J Virol, 2019
During antiretroviral therapy (ART), human immunodeficiency virus type 1 (HIV-1) persists as a latent reservoir in CD4+ T cell subsets in central memory (TCM), transitional memory (TTM), and effector memory (TEM) CD4+ T cells.
Kulpa DA, Talla A, Brehm JH, Ribeiro SP, Yuan S, Bebin-Blackwell AG, Miller M, Barnard R, Deeks SG, Hazuda D, Chomont N, Sékaly RP.   +11 more
europepmc   +3 more sources

Shocking HIV-1 with immunomodulatory latency reversing agents [PDF]

Seminars in Immunology, 2021
The "shock-and-kill" strategy is one of the most explored HIV-1 cure approaches to eliminate latent virus. This strategy is based on HIV-1 reactivation using latency reversing agents (LRAs) to reactivate latent proviruses (the "shock" phase) and to induce subsequent elimination of the reactivated cells by immune responses or virus-induced cytopathic ...
Anna Kula-Pacurar, Anthony Rodari, Gilles Darcis, Carine Van Lint   +3 more
openaire   +4 more sources

Lithium attenuates HIV-1 latency reversal in an autophagy-independent way. [PDF]

iScience
The major barrier to eradicate HIV-1 is its persistence in latently infected cells. Inducing deep latency to prevent HIV-1 reactivation in the absence of combined antiretroviral therapy (cART) remains a primary goal. Here, we evaluated the repurposing of lithium as an HIV-1 latency-promoting drug (LPA).
Abdalla AL, Guajardo-Contreras G, Chau BA, Niu M, Murooka T, Mouland AJ.   +5 more
europepmc   +3 more sources

Molecular chaperones at the host–virus interface: heat shock protein roles in HIV-1 and emerging insights for HIV-2 and dual infection [PDF]

Frontiers in Cellular and Infection Microbiology
Heat shock proteins (HSPs) are essential molecular chaperones involved in protein folding, cellular stress responses, and homeostasis. Recent studies reveal their critical and dual roles in the human immunodeficiency virus (HIV) life cycle, both ...
Sabastine Eugene Arthur, Sabastine Eugene Arthur, Kirk Klogo, Emmanuel Kobina Mensah, Maame Ama Pentsiwa Cudjoe, Maame Ama Pentsiwa Cudjoe, Adomia Baaba Mensah, Nyamekye Amoabeng Ankrah, Catherine Laaripuoh Omosule, Catherine Laaripuoh Omosule, Evelyn Yayra Bonney, George Boateng Kyei, George Boateng Kyei, George Boateng Kyei, George Boateng Kyei   +14 more
doaj   +2 more sources